Format

Send to

Choose Destination
BMC Complement Altern Med. 2018 Sep 6;18(1):248. doi: 10.1186/s12906-018-2316-4.

Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice.

Author information

1
Department of Chemistry, Chinese Culture University, Taipei, 11114, Taiwan.
2
Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
3
Department of Applied Science, National Tsing Hua University South Campus, Hsinchu, 30014, Taiwan.
4
Department of Biochemical Science and Technology, National Chiayi University, Chiayi, 60004, Taiwan.
5
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, 11221, Taiwan.
6
Program in Clinical Drug Development of Chinese Herbal Medicine, Taipei Medical University, Taipei, 11001, Taiwan.
7
Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, No. 155, Sec. 2, Linong St., Beitou District, Taipei, 11221, Taiwan. chengh@ym.edu.tw.
8
Department of Earth and Life Sciences, University of Taipei, Taipei, 11153, Taiwan. chengh@ym.edu.tw.

Abstract

BACKGROUND:

Persistent hepatitis B virus (HBV) infection causes liver cirrhosis and hepatocellular carcinoma and constitutes a major worldwide health problem. Currently, anti-HBV drugs are limited to peginterferon and nucleos(t)ide analogs, which are costly and have considerable side effects; the development of novel, effective anti-HBV agents is crucial.

METHODS:

Catechins are a major group of compounds found in green tea extract and epigallocatechin gallate (EGCG) has been shown to have antiviral properties, including inhibition of cellular entry by HBV. FRG (Fah-/-/ Rag2-/-/ IL-2Rγ/-) mice were used in this study to generate chimeras carrying human primary hepatocytes, to facilitate investigation of the inhibitory effect of EGCG on HBV infection.

RESULTS:

Here, we show the inhibitory effect of EGCG on HBV infection and replication in HuS-E/2 cells. The inhibitory effect of EGCG on HBV infection in vivo was confirmed by monitoring HBV DNA and HBsAg in serum and immunostaining the liver tissues of the human liver chimeric mice.

CONCLUSIONS:

The effects of EGCG suggest a robust strategy for the treatment of HBV infection and EGCG may have therapeutic potential for the treatment of HBV-associated liver diseases.

KEYWORDS:

EGCG; HBsAg; Hepatitis B virus; Human liver chimeric mice

PMID:
30189898
PMCID:
PMC6127945
DOI:
10.1186/s12906-018-2316-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center